Cancer Genetic Mutation Testing and Information Services
First written in FY2017. 1 of 3 entries say "Advanced", first in FY2019. Latest entry: FY2021.
0 other companies' latest entry also says "Restated".
- FY2021RestatedAnnual report
「For the cancer genetic mutation testing technology introduced from KEW, Inc. of the United States in February 2017, デンカ, KEW, Inc., and their joint venture, デンカ・キュー・ジェノミクス, are continuing initiatives aimed at filing an application for regulatory approval.」
Continuing initiatives aimed at filing an application for regulatory approval for cancer genetic mutation testing through collaboration with KEW, Inc. and the joint venture. - FY2019AdvancedAnnual report
「For the cancer genetic mutation testing technology introduced from KEW, Inc. of the United States in February 2017, we are pursuing initiatives aimed at filing an application for regulatory approval through collaboration among デンカ, KEW, Inc., and their joint venture, デンカ・キュー・ジェノミクス, while promoting collaborative research with Japanese university medical faculties and other research institutions.」
For cancer genetic mutation testing, collaboration with Japanese research institutions has progressed to the stage of pursuing an application for regulatory approval. - FY2017First statedAnnual report
「We jointly established デンカ・キュー・ジェノミクス合同会社 with KEW, Inc. of the United States for the cancer genetic mutation testing and information services business.」
Established デンカ・キュー・ジェノミクス through a joint investment with KEW, Inc., creating the foundation to launch cancer genetic mutation testing and information services.